UNSPSC 51121925: Ramnodigin

This classification denotes a cardiotonic agent with the molecular formula C29H44O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z8SRY7BR30, chemically known as 14-hydroxy-3beta-((2,3,6-trihydroxy-alpha-l-erythro-hexopyranosyl)oxy)-5beta-card-20(22)-enolide but generally known as ramnodigin, which bears US NIH Compound Identifier 3052773. European Medicines Agency schedules Ramnodigin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10251MIG.

UNSPSC 51121925 Ramnodigin, a Commodity code, covers pharmaceutical preparations that state and local governments procure primarily for emergency medical services and pharmacy benefit programs. Recent solicitations show state and local buyers acquiring advanced life support medications (epinephrine, labetalol, adenosine, diltiazem), generic multi-source pharmaceuticals through cooperative purchasing vehicles, and direct-to-manufacturer prescription programs. Fire rescue departments, state health agencies, and cooperative purchasing alliances are the primary issuing bodies, with activity concentrated in Florida, Texas, and Minnesota. The code captures both immediate critical-care medication needs and broader pharmacy benefit management initiatives, reflecting governments' dual focus on emergency response supply chains and cost-effective pharmaceutical distribution.

The City of Tampa's Purchasing Department solicited advanced life support medications (IFB 26P00188, due April 8, 2026) for Tampa Fire Rescue with an estimated contract value of $40,000, requiring sealed bids through the OpenGov eProcurement Portal and a one-year initial term with two one-year renewal options; this solicitation included a 5 percent SLBE bid discount. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP (S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed across state and local facilities in Minnesota and Oregon, requiring vendors to work through AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson, with a two-year contract term effective July 1, 2026. The Texas Health and Human Services Commission issued a Request for Information (HHS0017013, posted April 3, 2026) to explore direct-to-manufacturer prescription program capabilities, signaling future formal procurement development. No award values or set-asides were specified in the Texas RFI, as it functions as preliminary market intelligence to inform subsequent RFP strategy.